Cellular Therapy

MD IQ

Conference Coverage

CAR T-cell therapy advances in CLL

ORLANDO – The safety and clinical activity of the CD19-directed CAR T-cell agent justifies moving forward with phase 2 investigation, researchers...

Conference Coverage

PT-Cy bests conventional GVHD prophylaxis

ORLANDO – Rates of progression/relapse, progression-free survival, and overall survival were similar between posttransplant cyclophosphamide and...

Pages